500 related articles for article (PubMed ID: 26894799)
1. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.
Robles NR
Clin Drug Investig; 2016 Jun; 36(6):421-31. PubMed ID: 26894799
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for treatment of anemia of chronic kidney disease.
Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
[TBL] [Abstract][Full Text] [Related]
3. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B; Mariusz S; Jacek R
Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
[TBL] [Abstract][Full Text] [Related]
4. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
6. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
7. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
8. [Erythropoietin stimulating agents in chronic kidney disease: indications and contraindications].
Żebrowski P; Mieczkowski M
Wiad Lek; 2016; 69(5):753-755. PubMed ID: 28033602
[TBL] [Abstract][Full Text] [Related]
9. [Clinical management of anemia in patients with CKD].
Rivera RF; Alibrandi MTS; Di Lullo L; Fioccari F
G Ital Nefrol; 2017 Mar; 34(Suppl 69):20-35. PubMed ID: 28682026
[TBL] [Abstract][Full Text] [Related]
10. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
Locatelli F; Del Vecchio L
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
[TBL] [Abstract][Full Text] [Related]
11. New Treatment Approaches for the Anemia of CKD.
Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
[TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis-stimulating agents--time for a reevaluation.
Unger EF; Thompson AM; Blank MJ; Temple R
N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
[No Abstract] [Full Text] [Related]
13. Erythropoietin and resistant hypertension in CKD.
Boyle SM; Berns JS
Semin Nephrol; 2014; 34(5):540-9. PubMed ID: 25416663
[TBL] [Abstract][Full Text] [Related]
14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
15. [Erythropoiesis stimulating agents in clinical practice].
Niemczyk L; Dębowska M
Wiad Lek; 2014; 67(3):413-5. PubMed ID: 25782201
[TBL] [Abstract][Full Text] [Related]
16. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
Wish JB; Coyne DW
Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
[TBL] [Abstract][Full Text] [Related]
17. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
Thavarajah S; Choi MJ
Am J Kidney Dis; 2019 Nov; 74(5):667-674. PubMed ID: 31395400
[TBL] [Abstract][Full Text] [Related]
18. Anemia of chronic kidney disease: Treat it, but not too aggressively.
Nakhoul G; Simon JF
Cleve Clin J Med; 2016 Aug; 83(8):613-24. PubMed ID: 27505883
[TBL] [Abstract][Full Text] [Related]
19. Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia.
Kuragano T; Nakanishi T
Contrib Nephrol; 2018; 196():52-57. PubMed ID: 30041204
[TBL] [Abstract][Full Text] [Related]
20. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective.
Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C
Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]